These two tools are, as I said, structural modeling, but they’re paired with large multi species, antibody databases. And that’s a really key part. If you’ve been through as many programs as we have over many years, deep collaborations with partners. And we then use that and we also leverage AI and machine learning here as well. And that is something else that I think our partners value, may not be as well known that we do that because to us, it’s good science, you weave it together. But unless you’ve got that biological intelligence source that was built over millions of years of evolution, those tools are hindered without that. We obviously leverage that as well. And we’re proud of the fact that that we advanced programs for our partners, pairing those internal capabilities, obviously with our novel transgenic animals.
Yuan Zhi: Yes, got it. That’s very helpful and thorough review of your platform. And Kurt maybe one for you, understand the uniqueness of your business. As you know there are active royalty deals on the markets. And can you remind us the discussion you may have had with these loyalty players to monetize your future royalty or potential collaborations or any of your thoughts will be very helpful?
Kurt Gustafson : Sure. These folks come and we have conversations with them. So we’re certainly aware that those are options that are out there. I think in terms of where we stand today, though, as I kind of talked about, we’re sitting in a strong capital position, right. This business in some ways a fairly mature business. It’s fairly close to breakeven cash flow. And given the amount of money that we have on the balance sheet today, we’re sort of set. As I look forward into the future, I don’t foresee the need to raise additional capital, barring some sort of acquisition that we might do. So we talk to those people. We were aware of what’s out there, but it’s sort of not part of anything that we’re contemplating at this point.
Yuan Zhi: Got it. That’s all our question. Thank you.
Kurt Gustafson : Great, thanks Yuan.
Operator: Thank you, Mr. Foehr, there are no further questions at this time. Please proceed.
Matt Foehr : Great. Thanks. I’d like to thank you all for joining today’s call, and for your questions and engagement. And as I close out the call here I also want to take a really quick moment to thank our employees as completing a split out — from a public company is a substantial project and takes some business stamina, relentless attention to detail and collaborative teamwork to do. And we’ve had that to do that all while running and growing the business, support our partners, innovating around the technology as well. So I want to I want to thank the employees. And I will say that together, we feel great about our positioning and our ability to build value for all stakeholders, which includes, of course our partners, and of course importantly, you the investors.
So we keep these things top of mind here at OmniAb. And so just wanted to close out with that. I’ll also mention that we’ll be at a couple of investor conferences in the near term. We’ll be at the H. C. Wainwright BioConnect Conference at the NASDAQ headquarters in New York City on May 2, and we’re also planning on attending the EF Hutton Global Conference on May 11, which is also in New York City. So we’ll look forward to keeping you updated on our progress and hope everybody has a great day. Thank you.
Operator: Thank you. That does conclude our conference for today. Thank you all for participating. You may now disconnect.